They have verified that full vaccination against COVID-19 reduces the possibility of transmission even among people living with it

Clinical trials last year showed the high protection that COVID-19 vaccines offer to reduce complications and deaths if people are exposed to the coronavirus. As vaccination plans are implemented in each country, questions are raised and more benefits are being discovered. A scientific study in the Netherlands has set out to assess the real world of how low the infection of the coronavirus that causes the disease COVID-19 will be when people actually reach the doses to complete the plan. They found that lfull vaccination It not only provides protection to the person receiving it, but also helps prevent transmission of infection between cohabitants.

Study led by scientists from Center for Infectious Disease ControlWhich is based on the National Institute of Public Health and the Environment of the Netherlands. Prior to its implementation, researchers considered this to be an important issue when making epidemic predictions in the near future, due to the need for various control measures. It was necessary to know to what extent vaccinations reduce the possibility of transmission of infected vaccines.

They were based on routine follow-up data from contacts in the Netherlands, and sought to estimate vaccine efficacy against transmission and vaccine efficacy against infection between households and other contacts. Confirmed cases of coronavirus infection between February 1 and May 27, 2021.

The worrying alpha variant, which was discovered in the UK in October last year, was the dominant variant in the region at the time. Now, however, the delta variant is most prevalent in Europe. In July, the Netherlands saw a spike in cases and tightened requirements for travelers. 55.7% of Dutch adults have already been fully vaccinated and 83.5% have received a dose.

In the Netherlands, mRNA vaccines from Pfizer/BioNTec and Moderna, a vaccine developed by Oxford University and AstraZeneca (with non-recurrent viral vector), and a single-dose vaccine from Johnson & Johnson were used.

The scientists found that secondary transmission rates drop from 31% to 11% if the indicator patient is fully vaccinated A study published in the Journal of Public Health European watch. “This finding underscores the importance of full vaccination of close contacts of people at risk,” the researchers wrote.

To answer their research question, the scientists analyzed 113,582 index cases of adults and 253,168 close contacts of all ages. They explained that 5,394 people fell into both categories: Close contact was also classified as an indicator condition when the result was positive. Less than 1% (0.5%) of the diseased cases were fully vaccinated, while 1.8% were partially vaccinated. In the case of close contacts, 2.1% were fully vaccinated and 1.7% were partially vaccinated.

The transmission rate to close contacts was 31% for family members exposed to non-immunized indicator patients, but 11% if the indicator patient was fully vaccinated. These percentages indicate that the vaccine’s adjusted efficacy against transmission is 71%.

Differences were found in the level of infection and in different vaccines. By type of vaccine, the effectiveness of the vaccine in reducing coronavirus transmission was estimated by 58% for the AstraZeneca/Oxford vaccine, 70% for Pfizer/BioNTech, 88% for Moderna and 77% for Johnson & Johnson. Only partial vaccination resulted in a level of efficacy in reducing transmission of between 15% and 51%.

In the case of close contacts who are not family members, the researchers say the vaccine’s effectiveness in preventing transmission appeared to be 22%. Which they suggest may be due to index case misclassification. In this regard, the researchers acknowledged that there were limitations to the study.

“While we try to reduce misclassification of index cases and contacts by excluding index cases infected at home and contacts who developed symptoms before or at the same time as the index, It is plausible that in some cases the transmission path or transmission event has been reversed [a través de] Another source (especially in the case of non-local connections)Write to researchers saying that this may cause the modified level of vaccine efficacy to be underestimated to avoid infection.

Furthermore, the authors note that, “Because our analysis of household contacts was limited to reported non-infected index cases in the home, it is likely that the majority of these index cases sought testing because they had symptoms. It may be that asymptomatic cases were misclassified. false as indicator states in the family, where in fact an asymptomatic family member was the source of the transition to the alleged indicator state and a third family member. If the vaccine is likely to be asymptomatic, this source of misclassification may lead to an overestimation of the vaccine’s level of efficacy in preventing transmission.”

Overall, the researchers reported that the adjusted efficacy of the vaccine for fully vaccinated family contacts after confirmed exposure was 75% and 79% for other contacts.

last June, There was a study in Israel that also found that vaccinating adults has benefits for children. There, the slogan of the vaccination campaign is “palm by shoulder” since last December 19. The study showed that the shoulder position for immunization not only reduces infection in people who get the shots and reduces deaths, but it also helps children and teens who didn’t get vaccinated.

The positive effect of vaccination has been proven on people who have not yet been vaccinated Through a study conducted by scientists from the Israeli Technion Institute of Technology, the Maccabi Center for Innovation and Research, and Tel Aviv University in Israel, who agreed to speak with Infobae. The study was published in the journal nature medicine June 10.

“Our study shows that vaccination against COVID-19 is important for reducing transmission in the community, and that the more people vaccinated, the more unvaccinated people will be protected,” he said in June. Infobae Scientist Roy Kishoni, who with his team devoted himself to researching the evolution of microbes and the problem of antibiotic resistance before the epidemic, is now focused on studying the effect of vaccination against the Corona virus.

Read on: